Navigation Links
Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
Date:1/22/2008

Fourth Quarter 2007 Financial Results

VANCOUVER, Jan. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2007.

Thursday, February 14, 2008 at 11:00 AM ET

(8:00 AM Pacific, 9:00 AM Mountain, 10:00 AM Central)

Dial information is as follows:

North America (toll-free): (866) 510-0711

International: (617) 597-5379

Enter passcode: 91184096

A live webcast will be available to all interested parties through Angiotech's website at http://www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the conference call at approximately 8:00 AM ET (5:00 AM Pacific, 6:00 AM Mountain, 7:00 AM Central).

A replay archive of the conference call will be available until February 21, 2008.

Replay information is as follows:

North America: (888) 286-8010

International: (617) 801-6888

Enter passcode: 85112963

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX, ANP) please visit our website at

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Angiotech and Symphony Medical Announce Licensing Agreement
2. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
3. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
4. Angiotech to participate in RBC 2007 Healthcare Conference
5. Angiotech to participate in Bank of America 2007 Credit Conference
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Angiotech to participate in UBS Global Life Sciences Conference
10. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... -- Intarcia Therapeutics, Inc. delivered two pres...nuous delivery of exenatide) program for the treat...es Technology Meeting in San Francisco, CA: ,, ...01/SFTU126LOGO ) ,, Continuous Subcutaneous D...ucose, HbA1c and Reduces Weight in a 28-day Phase ...
(Date:11/5/2009)... , Fuel economy ratings for the new 2010 model y...nomy.gov web site, which Oak Ridge National Labor...ent of Energy and the U.S. Environmental Protectio...fuel economy list are hybrid electrics, led by the...t proves that hybrids have gone mainstream," said ...
(Date:11/5/2009)...e/ -- The endangered black-footed ferrets inhabit ...arnivore feeds on prairie dogs. The prairie dogs...opulation die-offs in towns occur. The U.S. Fish ...ret breeding program and has been releasing traine...tat. Unfortunately, plague can sweep through and ...
(Date:11/5/2009)...all/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX... and CEO of Imagenetix, will be presenting the Com... on Thursday, December 3rd, at 10:30 AM PST at the...,, LD MICRO is a by-invitation only newsletter ... in the micro-cap space. Since 2002, the firm has ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2
...n of the Board -, MADISON, N.J., April 24 Wyeth ...obert Essner, 60, has decided to retire,from the C...d the position,of Chairman since January 2003 and ...1 to 2007. The Company,s Board of Directors has el... Executive Officer, to the,additional position of ...
...Inc.,(Nasdaq: HOLX ), a diversified medical techn...imaging products and interventional devices dedica...y announced plans to release its,second quarter fi...08 at,8:00 a.m. (eastern). In conjunction with the...n Thursday, May 1, 2008 at 9:00 a.m. (eastern)., ...
...ewswire-FirstCall/ -- China Sky One,Medical, Inc. ...lletin,Board: CSKI), a pharmaceutical company for ...s Republic of China ("PRC"), today announced it,ac...ina Pharmaceutical"), a,recently formed corporatio... 2008., China Sky One Medical, Inc., through its ...
Other Biology Technology:Wyeth Chairman Robert Essner Announces June 27 Retirement 2Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens 2China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 2China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 3
(Date:11/9/2009)...e of butterfly wings has inspired a 3.2m, three-ye...ation in the fields of security, energy and the en...nal technology company QinetiQ have just signed a ... based on groundbreaking physical sciences researc...ists from the University of Exeter and QinetiQ wil...
(Date:11/9/2009)...rlands, November 09, 2009 / b3c newswire / - To...and Seventh Wave, an American organization for con...companies have signed a letter of intent with rega...els TIM. The letter of intent proposes a collabora...tems for commercialization in North America. The T...
(Date:11/9/2009)...cientists and industry leaders from around the wor... AACR-NCI-EORTC Molecular Targets and Cancer Thera...re groundbreaking information on important cancer ...x disease and to treat it effectively we need a gr...ce at the molecular level," said Lewis Cantley, Ph...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Take A Swing Against Breast Cancer 21 51913 1Take A Swing Against Breast Cancer 21 51913 2ANDRES F ALONSO ESQ a Partner in the Law Firm of PARKER WAICHMAN ALONSO LLP Was Appointed Co Lead Counsel to the Plaintiffs Steering Committee in 51908 1ANDRES F ALONSO ESQ a Partner in the Law Firm of PARKER WAICHMAN ALONSO LLP Was Appointed Co Lead Counsel to the Plaintiffs Steering Committee in 51908 2Mettler Toledo International Inc to Host Second Quarter 2009 Earnings Conference Call 51904 1
...NY, October 30, 2008 Bayhill Therapeutics, Inc., ...seases, and the Juvenile Diabetes Research Foundat... 1 diabetes research, today announced a partnershi...inical trial of BHT-3021, a DNA vaccine to reverse..., BHT-3021 is an antigen-specific immunotherapeut...
...raits that we look for typically include a sense o...isma. However, a recent study suggests that it is ...cation skills that determine who is chosen as lead...at there is a gender bias when selecting leaders; ...end on the specific situation that a group finds i...
...rs at Georgetown University Medical Center have di...become resistant to tamoxifen, the world,s largest...ug. They say the findings could provide a way to i...ng from the drug, allowing doctors to try another ...f the journal Cancer Research, the researchers s...
Other Biology News:Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 2Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 3Gender biases in leadership selection during competitions within and between groups 2Gender biases in leadership selection during competitions within and between groups 3'New' estrogen receptor found to be key player in tamoxifen resistance 2'New' estrogen receptor found to be key player in tamoxifen resistance 3
...e a group of enzymes involved in matrix degradatio...ase family ten exist in soluble form whereas MT-MM...T2-MMP, MT3-MMP also known as MMP14, MMP15, MMP16 ...main anchoring them to the cell surface. They have...
CD43 MicroBeads, rat from Miltenyi Biotec
... IKATUBE ULTRA TURRAX Tube Disperser System from I...ystem. It offers a cleaner, safer, and more effici...ocesses sample volumes from 2 to 15 ml inside seal...ers can choose one of 4 different tube types. Each...
RNaseAlert Lab Test Kit from Ambion
Biology Products: